Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight’s lead product, BST-236 (aspacytarabine), is an innovative proprietary anti-metabolite which addresses unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following completion of a Phase 1/2a study which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard of care chemotherapy. A Phase 2 study in relapsed/refractory AML and myelodysplastic syndrome (MDS) will be launched in 2020 under a collaboration agreement recently signed with the European cooperative group, GFM.
View Top Employees from Biosight Ltd.Website | http://www.biosight-pharma.com |
Employees | 7 (7 on RocketReach) |
Founded | 2000 |
Phone | +972 4-958-1519 |
Technologies |
JavaScript,
HTML,
Twitter
+7 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Health Care, Drug Discovery, Pharmaceutical development, Pharmaceutical, Biotechnology, Pro-drugs, Therapeutics, Leukemia treatment, Non-toxic chemotherapy, Targeted chemotherapy |
Web Rank | 19 Million |
Keywords | Biosight |
Looking for a particular Biosight Ltd. employee's phone or email?
Liat Flaishon is the Vice President Medical Affairs of Biosight Ltd..
7 people are employed at Biosight Ltd..